CES2 and metabolic dysfunction-associated steatohepatitis: [8] showed markedly reduced serine hydrolase activity of CES2 in the liver of obese individuals without NAFLD, implicating that reduced CES2 (and conceivably Ces2a) expression is an early event in NAFLD/NASH progression.